Research material and lot documents
BPC-157 and TB-500 have been tested together in one controlled animal experiment, a 2026 rat Achilles tendon study, and the October 15, 2026 searches found no controlled human trial of the pair. The pair is sold as the Wolverine stack, described on the Wolverine peptide page. Each peptide has its own record on the TB-500 vs BPC-157 page.
Two records include a combination group.
A 2026 rat study tested BPC-157, TB-500 and the pair in tendon repair. Source: 2026 BPC-157 and TB-500 rat study, PMID 42542926.
A 2021 clinic chart review of knee pain included four people who received BPC-157 with thymosin beta-4. Source: 2021 knee-pain chart review, PMID 34324435.
On October 15, 2026, a PubMed search for both peptide names returned nine records: one experimental study and eight review articles. Source: dated PubMed search for BPC-157 and TB-500. A search that also accepts the name thymosin beta-4 returned 11 records and adds the 2021 chart review. Source: dated PubMed search that adds thymosin beta-4. ClinicalTrials.gov returned no record for the pair. Source: dated ClinicalTrials.gov search for BPC-157 and TB-500. A name search can miss work that uses other names for these peptides.
The authors cut and repaired the Achilles tendon in 32 male Sprague-Dawley rats and assigned eight rats to each of four groups: control, BPC-157, TB-500 and the combination. After four weeks they measured the load each tendon bore before failing and scored tendon structure and collagen on stained sections. Source: 2026 rat Achilles tendon study, Joint Diseases and Related Surgery, PMID 42542926.
The authors reported higher maximum load in the BPC-157 and TB-500 groups than in controls, with statistical significance in the TB-500 group only. They reported significantly lower total Bonar scores in the TB-500 group and significantly lower total Movin scores in the TB-500 and combination groups than in controls. The BPC-157 group had numerically lower scores that did not reach significance. The authors wrote that combined treatment "did not confer additional benefits compared to either agent alone."
They called the study exploratory. Their abstract says the lack of an added effect may reflect shared downstream pathways and that this idea needs further experimental confirmation. The abstract does not say whether the TB-500 material was the acetylated fragment that FDA records under that name. The result belongs to this rat model of tendon repair.
The authors reviewed one clinic's charts from 2019 to 2020 and reached 16 of 17 patients by phone. Twelve had received BPC-157 alone and four had received BPC-157 with thymosin beta-4, which the abstract names TB4 and not TB-500. The authors reported improvement in 11 of the 12 and in 3 of the 4. They used no standard tools to measure function, quality of life, stiffness or daily activities, and the abstract describes no comparison group. Source: 2021 knee-pain chart review, Alternative Therapies in Health and Medicine, PMID 34324435.
A 2026 scoping review of six peptides, including BPC-157 and TB-500, found that 67% of the identified publications used animal models and that human studies were few and mostly lacked rigorous design. The authors concluded that the claimed benefits "remain unsubstantiated by current human trials." Source: 2026 peptide scoping review, American Journal of Sports Medicine, PMID 42578445.
A 2025 systematic review of BPC-157 included 36 studies, 35 preclinical and one clinical, and reported that no clinical safety data were found. Source: 2025 BPC-157 systematic review, HSS Journal, PMID 40756949.
FDA's bulk drug substances page, content current as of April 22, 2026, lists BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" under bulk drug substances nominated but withdrawn. For BPC-157 it says FDA "has identified no, or only limited, safety-related information" for the proposed routes. For the TB-500 fragment it says FDA "has not identified any human exposure data." Source: FDA bulk drug substances page, content current as of April 22, 2026.
On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee discussed BPC-157-related and TB-500-related substances for inclusion on the 503A Bulks List. FDA says advisory committees make non-binding recommendations. Source: FDA meeting page for July 23-24, 2026. FDA's briefing documents for that meeting say, for each substance, "we believe the evaluation criteria weigh against placing" it on the list. Sources: FDA briefing document on BPC-157 and FDA briefing document on TB-500. The same documents report that the World Anti-Doping Agency lists BPC-157 under section S0 and TB-500 under section S2.3 of its Prohibited List. The Associated Press reported that the panel "narrowly recommended easing access to several peptides," a group that included BPC-157 and TB-500. Source: Associated Press report, July 23, 2026. The bulk drug substances page above carried the content date April 22, 2026 when read on October 15, 2026, so it predates the meeting.
The BPC-157 briefing document also summarizes a report to FDA's adverse event system about a woman who used a product containing BPC-157 and TB-500 that was labeled for research purposes only. The report describes diffuse hyperpigmentation and darkening of the gums, which returned when she used the product again. FDA wrote that the events were likely due to the product because they recurred, and that because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported events. Source: FDA briefing document on BPC-157, July 23-24, 2026.
That the pair works better than either peptide alone. The one controlled comparison, in rats, reported no added benefit.
An effect in people. The human records are a small chart review without a comparison group and a two-person pilot study of BPC-157 alone (see the TB-500 vs BPC-157 page), and the reviews above describe the human evidence as limited.
Safety data for the pair in people. FDA's records describe limited or missing human safety information for each component.
A lot report documents the material in one vial. It does not document an effect in an experiment or in people. Curo's lot certificate library publishes reports by lot number. The Wolverine peptide for sale page explains which fields to read, and the Wolverine peptide page explains what the name covers.